Impact of the common MTHFR 677C→T polymorphism on blood pressure in adulthood and role of riboflavin in modifying the genetic risk of hypertension: evidence from the JINGO project

Mary Ward, Catherine F. Hughes, J. J. Strain, Rosie Reilly, Conal Cunningham, Anne M. Molloy, Geraldine Horigan, Miriam Casey, Kevin McCarroll, Maurice O’Kane, Michael J. Gibney, Albert Flynn, Janette Walton, Breige A. McNulty, Adrian McCann, Laura Kirwan, John M. Scott, and Helene McNulty

Abstract

Background: Genome-wide and clinical studies have linked the 677C→T polymorphism in the gene encoding methylenetetrahydrofolate reductase (MTHFR) with hypertension, whilst limited evidence shows that intervention with riboflavin (i.e. the MTHFR co-factor) can lower blood pressure (BP) in hypertensive patients with the variant MTHFR 677TT genotype. We investigated the impact of this common polymorphism on BP throughout adulthood and hypothesised that riboflavin status would modulate the genetic risk of hypertension.

Methods: Observational data on 6076 adults of 18–102 years were drawn from the Joint Irish Nutrigenomics Organisation project, comprising the Trinity-Ulster Department of Agriculture (TUDA; volunteer sample) and the National Adult Nutrition Survey (NANS; population-based sample) cohorts. Participants were recruited from the Republic of Ireland and Northern Ireland (UK) in 2008–2012 using standardised methods.

Results: The variant MTHFR 677TT genotype was identified in 12% of adults. From 18 to 70 years, this genotype was associated with an increased risk of hypertension (i.e. systolic BP ≥ 140 and/or a diastolic BP ≥ 90 mmHg): odds ratio (OR) 1.42, 95% confidence interval (CI) 1.07 to 1.90; P = 0.016, after adjustment for antihypertensive drug use and other significant factors, namely, age, male sex, BMI, alcohol and total cholesterol. Low or deficient biomarker status of riboflavin (observed in 30.2% and 30.0% of participants, respectively) exacerbated the genetic risk of hypertension, with a 3-fold increased risk for the TT genotype in combination with deficient riboflavin status (OR 3.00, 95% CI, 1.34–6.68; P = 0.007) relative to the CC genotype combined with normal riboflavin status. Up to 65 years, we observed poorer BP control rates on antihypertensive treatment in participants with the TT genotype (30%) compared to those without this variant, CT (37%) and CC (45%) genotypes (P < 0.027).

(Continued on next page)
Conclusions: The MTHFR 677TT genotype is associated with higher BP independently of homocysteine and predisposes adults to an increased risk of hypertension and poorer BP control with antihypertensive treatment, whilst better riboflavin status is associated with a reduced genetic risk. Riboflavin intervention may thus offer a personalised approach to prevent the onset of hypertension in adults with the TT genotype; however, this requires confirmation in a randomised trial in non-hypertensive adults.

Keywords: Hypertension, Blood pressure, Folate polymorphism, MTHFR, Riboflavin, Personalised treatment, Prevention

Background

Hypertension is the leading risk factor contributing to all-cause death in every region in the world, estimated to affect 1.13 billion people globally and account for over 9 million deaths annually, predominantly from cardiovascular disease (CVD) [1–3]. The relationship of blood pressure (BP) with disease is age-specific and most pronounced in adults 40–69 years, where the risk of CVD is estimated to double for each 20 mmHg rise in systolic BP [4]. Recent reports have highlighted the importance of targeting lifestyle and treatment strategies at the individual level in order to improve cardiovascular health [1, 5], and genome-wide association studies (GWAS) have identified specific genes linked with BP which could lead to personalised treatments for hypertension based on genetic characteristics. The earliest of such studies tested 2.5 million single nucleotide polymorphisms (SNPs) and identified eight genetic loci associated with BP, including a region near the gene encoding the folate-metabolising enzyme methylenetetrahydrofolate reductase MTHFR [6], findings confirmed by subsequent GWAS [7].

Of greater relevance to health, clinical studies have linked this gene with BP, with meta-analyses of case-control studies showing that the 677C→T polymorphism in MTHFR is associated with an increased risk of hypertension by 36–87% [8–10]. Previously, the role of this polymorphism in CVD has been studied extensively in relation to the well-recognised phenotype, elevated homocysteine, whilst the relationship with BP is relatively under-investigated. The variant MTHFR 677TT genotype, which affects 10% of adults worldwide [11], is however reported to increase the risk of CVD (especially stroke) by up to 40%, albeit with a large geographical variation in the extent of excess risk, consistent with a gene-environment interaction [12–14]. In this regard, only folate was previously considered, but emerging evidence suggests that riboflavin—required in the form flavin adenine dinucleotide (FAD) as a cofactor for MTHFR—may be a key modifying factor linking this polymorphism with CVD via a novel and genotype-specific effect on BP [14]. In three small randomised controlled trials, we previously demonstrated lowering of systolic BP by 6 to 13 mmHg in response to riboflavin when targeted at hypertensive patients with the variant MTHFR 677TT genotype [15–17].

No previous study has investigated the contribution of the MTHFR 677C→T polymorphism to BP within generally healthy adults or identified a potential prevention strategy to reduce the onset of hypertension in those genetically at-risk. The aim of this study was therefore to examine the impact of this polymorphism on BP throughout adulthood and to assess the role of riboflavin in modulating the genetic risk of hypertension. We hypothesised that this polymorphism is associated with high BP independently of its association with homocysteine and that riboflavin status would modulate the genetic risk of hypertension.

Methods

Design and participants

Data for this investigation were drawn from two cohorts, the Trinity-Ulster Department of Agriculture (TUDA) cohort study and the National Adult Nutrition Survey (NANS) of Ireland, both forming part of an All-Ireland initiative under the Joint Irish Nutrigenomics Organisation (JINGO) project (http://www.ucd.ie/jingo/; accessed May 2020). The TUDA study (ClinicalTrials.gov Identifier: NCT02664584) comprises a cross-sectional cohort of 5186 older adults (≥60 years), with the primary aim of investigating nutritional factors and gene-nutrient interactions in the development of chronic diseases of ageing. Eligible participants were community-dwelling, non-institutionalised adults, born on the island of Ireland. Participants were recruited using standardised protocols during the period of 2008 to 2012, either from GP practices in the Northern and Western Trusts in Northern Ireland (UK) or from hospital outpatient clinics at the Department of Medicine for the Elderly at St. James’s Hospital Dublin in the Republic of Ireland, as previously detailed [18]. Over a similar period (2008 to 2010), detailed dietary, biomarker, health and lifestyle data were collected for the NANS cohort, a nationally representative sample of Irish adults. Eligible participants were healthy adults aged 18–102 years, not pregnant or...
breast-feeding. Full sampling and methodological details for NANS 2008–2010 have been described elsewhere [19]. Approval for both studies was granted from the relevant ethics committees in the UK and the Republic of Ireland, and all participants provided written informed consent at the time of recruitment.

Study measurements
For both the TUDA and NANS cohorts, relevant health and lifestyle information was obtained in face-to-face interviews conducted by trained researchers. Detailed information concerning medication and vitamin supplementation was collected. Confirmation of medication details was obtained by referring to the participant’s prescription; where this was unavailable during the interview, the details were collected from the participant via telephone shortly after the appointment. Blood samples collected at the time of the appointment were analysed for routine laboratory measurements in the participating local laboratories, whereas B vitamin status biomarkers were analysed centrally in specialist research laboratories at Ulster University or Trinity College Dublin using standardised procedures [16]. Of particular relevance, the analysis included the riboflavin biomarker, erythrocyte glutathione reductase activation coefficient (EGRac), widely accepted as the gold-standard measure of riboflavin status. This coefficient provides a measure of glutathione reductase enzyme saturation with its riboflavin-derived cofactor and is thus a functional biomarker of riboflavin status; a low EGRac value is considered to be normal, whilst higher values are indicative of suboptimal riboflavin status. DNA samples were analysed for several SNPs, including MTHFR 677C→T (rs1801133), by LGC Genomics (Hoddesdon, UK).

Trained researchers measured BP using standard operating procedures and clinical guidelines, using an A&D UA-787 digital blood pressure monitor (Cardiac Services, Belfast, UK) or OMRON M6 (Milton Keynes, UK), for TUDA and NANS cohorts, respectively, with the participant in the supine position following a 5-min rest. In accordance with clinical guidelines [20], two BP measurements were taken from the reference arm, with a 5–10-min interval between each measurement to generate a mean BP value. In the case of a > 5-mmHg difference, a third BP measurement was taken after 10–15 min and the mean of the two BP measurements in closest agreement was used.

Study outcomes
The primary outcomes were systolic and diastolic BP, and occurrence of hypertension, by MTHFR genotype and MTHFR-riboflavin interaction. In accordance with British and European guidelines, hypertension was defined when a participant’s systolic BP was ≥ 140 mmHg and/or their diastolic BP was ≥ 90 mmHg; as per clinical guidance, these BP categories applied to all adults (> 18 years) [1, 20]. An additional study outcome was BP control on antihypertensive treatment by MTHFR genotype. Treatment was defined as taking medication to lower BP, as verified by the researcher against prescription details during or following the interview. Treated and controlled was defined as taking medication to lower BP and a recorded systolic BP of < 140 and/or diastolic BP < 90 mmHg.

Statistical analysis
Analysis was limited to participants with available MTHFR genotype and valid BP (Fig. 1). Before statistical analysis, tests for normality were performed and variables were log-transformed as appropriate. Participant characteristics were examined by MTHFR genotype and differences between groups were analysed using one-way between-groups analysis of variance (ANOVA) for continuous variables and χ² tests for categorical parameters. To account for multiple testing, the null hypothesis was rejected for \( P < 0.05 \) after post hoc Bonferroni correction at a family level. Logistic regression analysis was used to predict hypertension (as the categorical dependent variable) using relevant independent variables and examined the association of MTHFR genotype with the risk of hypertension after independently adjusting for established risk factors, including antihypertensive drug use (as a binary yes/no covariate adjustment). Multinomial regression was performed to enable the effect of the interaction between MTHFR genotype and biomarker status of riboflavin (i.e. deficient versus low versus normal) on the risk of hypertension to be assessed; odds ratios were calculated using MTHFR 677CC genotype combined with normal riboflavin status as the reference category. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS, version 21, SPSS UK Ltd., Chertsey Road, Surrey, UK).

Results
Study participants
From an original dataset of 6360 participants (i.e. combined TUDA \( n = 5186 \) and NANS \( n = 1174 \) cohorts), complete data for the current analysis were available for a total of 6076 participants (Fig. 1). Homozygosity for the MTHFR 677C→T polymorphism (TT genotype) was identified in 12% of the overall study sample (12.1% and 12.3% for TUDA and NANS cohorts, respectively; Additional file 1: Table S1 showing characteristics separately presented for TUDA and NANS cohorts). There were no significant differences in general participant characteristics among MTHFR genotype groups (Table 1). The expected phenotype was however evident in B vitamin biomarkers, with significantly higher plasma
homocysteine and lower red blood cell folate concentrations in the TT compared to CC or CT genotypes. General participant characteristics split by study sub-cohorts (i.e. TUDA and NANS cohorts) are provided as Supplementary material (Additional file 1: Table S1).

Impact of MTHFR genotype on blood pressure and risk of hypertension
Irrespective of MTHFR genotype, systolic BP showed an increase with age up to approximately 80 years, whereas diastolic BP increased until about age 60 years and then declined (Fig. 2). Examination of BP by MTHFR genotype, however, showed higher BP in the TT genotype group up to approximately 65 years compared to adults of the same age with CC or CT genotypes, with systolic and diastolic BP in the TT genotype observed to be typical of an adult several years older without this genetic variant. From about 65 years onwards, however, the BP phenotype associated with this polymorphism was less evident.

Among adults 18–70 years, logistic regression analysis showed that the MTHFR 677TT genotype was associated with an increased risk of hypertension: odds ratio (OR) 1.42, 95% confidence interval (CI) 1.07 to 1.90, after adjustment for antihypertensive drug use (as a binary covariate) and other significant covariates, namely, age, male sex, BMI, alcohol, total cholesterol and study cohort (Table 2), whereas homocysteine was not independently associated with the risk of hypertension (apart from in treated adults). The OR for risk of hypertension associated with the TT genotype remained similar whether the logistic regression analysis was performed in all participants up to 70 years, or split into those treated or not treated with antihypertensive drugs, albeit the relationship failed to reach statistical significance within either treated or untreated categories (owing to the loss of statistical power as a result of a 50% reduction in the sample size when split and considering that the variant TT genotype is represented by just 12% of the overall cohort). In contrast, when this analysis was conducted in the total sample (i.e. adults up to 90 years), MTHFR genotype was not significantly associated with hypertension, whilst all other determinants of hypertension were similar to those found in adults up to 70 years (not shown).

Likewise, no significant effect of MTHFR genotype on BP was observed when the total cohort was analysed, but among adults, 18 to 70 years, those with the TT genotype had significantly higher systolic and diastolic BP after adjustment for relevant covariates including antihypertensive drug use (Table 3). Among participants up to 70 years, 49% (n = 1255) were being treated with one or more antihypertensive drugs. Details of antihypertensive drug use and drug combinations among treated participants are shown in Table 4. Almost 60% of treated participants were treated with two or more
medications (57%, 57% and 59% for CC, CT and TT genotypes). For BP results among participants being treated/not treated with antihypertensive drugs by MTHFR genotype, see Additional file 1: Table S2.

In younger and middle-aged adults (18–65 years), significantly lower treated and controlled rates (defined as taking antihypertensive drugs and a recorded BP within the target range, i.e. systolic BP of < 140 and diastolic BP < 90 mmHg) were observed in the TT genotype (30%; n = 24) compared to CT (37%; n = 114) or CC (45%; n = 120) genotypes (P < 0.027); not shown.

**MTHFR genotype and riboflavin status in relation to hypertension**

The influence of riboflavin status in modifying the genetic risk of hypertension was then examined (Fig. 3). Based on functional status and response to low-dose riboflavin from previous reports [17], participants were categorised as having normal (EGRac ≤ 1.26), low (EGRac 1.26–1.40) or deficient (EGRac ≥ 1.40) riboflavin. Low or deficient riboflavin status (observed in 30.2% and 30.0%, respectively) exacerbated the risk of hypertension associated with this polymorphism, with a 3-fold increased risk (OR 3.00) for the TT genotype in combination with deficient riboflavin status (95% CI, 1.34–6.68; P = 0.007) relative to the CC genotype combined with normal riboflavin status as the reference category (Fig. 3). Among participants with the TT genotype, better riboflavin status was associated with a reduced risk (OR 1.62 (95% CI, 0.80–3.29; P = 0.179)) and normal riboflavin status with no excess genetic risk of hypertension. In contrast, deficient versus low versus normal riboflavin status did not alter the risk of hypertension among adults with CC or CT genotypes.

**Discussion**

Our study shows that from young adulthood to 70 years, the MTHFR 677TT genotype predisposes an individual to a systolic BP typical of an adult several years older without this genetic variant. Although this polymorphism was previously linked with BP, this is the first study

---

**Table 1 General participant characteristics by MTHFR genotype**

| MTHFR genotypea | CC (n = 2677) | CT (n = 2660) | TT (n = 739) | P valueb |
|------------------|-------------|-------------|-------------|---------|
| MTHFR genotype, n (%) | 2677 (44) | 2660 (44) | 739 (12) |         |
| Age, years | 68.9 (15.1) | 69.0 (15.5) | 68.6 (15.6) | 0.806 |
| Sex, male | 943 (35%) | 961 (36%) | 256 (35%) | 0.678 |
| Waist, cm | 94.5 (13.9) | 94.5 (14.1) | 94.7 (14.7) | 0.982 |
| Height, cm | 162.6 (10.2) | 162.9 (10.1) | 162.6 (10.0) | 0.619 |
| Weight, kg | 73.7 (16.5) | 73.7 (16.8) | 74.2 (17.3) | 0.853 |
| Body mass index, kg/m² | 27.8 (5.2) | 27.7 (5.4) | 27.9 (5.2) | 0.458 |
| Current smokers, n (%) | 359 (13%) | 355 (13%) | 89 (12%) | 0.530 |
| Alcohol Intake, units/week | 8.6 (12.2) | 8.8 (12.7) | 8.0 (11.3) | 0.402 |
| Serum triglycerides, mmol/L | 1.51 (0.84) | 1.56 (0.88) | 1.55 (0.78) | 0.087 |
| Serum total cholesterol, mmol/L | 4.68 (1.03) | 4.68 (1.06) | 4.73 (1.05) | 0.383 |
| Serum HDL, mmol/L | 1.51 (0.49) | 1.48 (0.45) | 1.49 (0.47) | 0.439 |
| Calculated LDL, mmol/L | 2.50 (0.88) | 2.50 (0.89) | 2.54 (0.88) | 0.472 |
| Serum creatinine, μmol/L | 86.3 (27.4) | 86.0 (26.4) | 85.9 (27.2) | 0.928 |
| Red blood cell folate, nmol/L | 1095 (579)a | 1088 (626)a | 971 (563)b | < 0.001 |
| Serum vitamin B12, pmol/L | 295 (155) | 295 (238) | 296 (238) | 0.194 |
| Riboflavin status, EGRac c | 1.35 (0.21) | 1.35 (0.21) | 1.34 (0.21) | 0.769 |
| Plasma homocysteine, μmol/L | 14.2 (5.4)a | 14.3 (5.4)a | 15.7 (6.8)b | < 0.001 |

Data are expressed as mean (standard deviation) or n (%).

aCC (wild type), CT (heterozygous), TT (homozygous variant), genotypes for the MTHFR 677C→T polymorphism

bP value from one-way ANOVA comparing genotype groups, following log-transformation of data for normalisation purposes, as appropriate. Different superscript letters (i.e. a, b) within a row indicate significant differences by Bonferroni post hoc test, whilst the same letter (i.e. a, a) indicates no significant differences. Level of significance (P < 0.003) adjusted for Bonferroni correction (n = 16). Categorical variables are assessed using chi-square analysis

cBiomarker status of riboflavin determined by the functional assay, erythrocyte glutathione reductase activation coefficient (EGRac); higher EGRac values indicate lower riboflavin status

---

Ward et al. BMC Medicine (2020) 18:318 Page 5 of 11
to examine the genetic risk of hypertension throughout adulthood and to identify the potential for riboflavin to modify the phenotype in affected adults at a younger age and before the onset of hypertension. The observed effect of MTHFR and its modulation by riboflavin in relation to hypertension risk were found to be independent of homocysteine, the typically reported phenotype linking this polymorphism with CVD.

We observed a pattern in the current study (irrespective of MTHFR genotype), whereby systolic BP increased into older age whereas diastolic BP increased until about 60 years and then declined, as previously reported [21, 22]. The results however showed that adults with the variant MTHFR 677TT genotype have higher systolic and diastolic BP compared to others of the same age with CC or CT genotypes. The BP phenotype was not evident above 70 years, presumably as a result of the confounding effect of other age-related determinants of BP. The reason we focussed on the period up to 70 years is because this is a time during which the relationship of BP with disease is most pronounced, with a reported doubling in the risk of CVD for each 20 mmHg rise in systolic BP [4]. The MTHFR 677TT genotype was associated with a 42% increased risk of hypertension in adults up to 70 years, after adjustment for antihypertensive drug use and other significant factors, namely, age, male sex, BMI, alcohol and blood cholesterol, whereas plasma homocysteine was not independently associated with hypertension risk. The extent of excess hypertension owing to this polymorphism is in good agreement with previous estimates from clinical studies, with reported odds ratios in meta-analyses ranging 1.36 (95% CI, 1.20–1.53) to 1.87 (1.31 to 2.68), for worldwide and Chinese populations, respectively [8, 10].

**Fig. 2** Systolic and diastolic blood pressure in adults 18–90 years by MTHFR genotype (n = 6070). Data grouped by deciles of age from the youngest 10%, to the oldest 10%, of study participants. Each line illustrates median systolic or diastolic blood pressure for adults by age: CC (green line), CT (amber line) and TT (red line) genotypes for the MTHFR 677C→T polymorphism.
affected adults could potentially develop hypertension at an earlier age than those without this genetic risk. Of particular relevance to cardiovascular medicine is the finding that response to routine BP treatment appears to be suboptimal in adults with the MTHFR 677TT genotype. Overall, 49% of participants 18–70 years in this study were under current treatment with antihypertensive drugs, a rate of treatment similar to that reported for adults 20–80 years in England (51%) and considerably less than in adults 20–80 years in the

### Table 2 Factors associated with risk of hypertension in adults 18–70 years

|                                | All (n = 2566) | On antihypertensive drugs (n = 1255) | Not on antihypertensive drugs (n = 1311) |
|--------------------------------|---------------|--------------------------------------|------------------------------------------|
|                                | OR 95% CI     | OR 95% CI                            | OR 95% CI                                |
| Age, years                     | 1.04 1.03–1.05| 1.01 0.98–1.04                       | 1.05 1.03–1.06                           |
| Sex, male                      | 1.86 1.50–2.32| 1.69 1.28–2.25                       | 1.77 1.23–2.56                           |
| BMI, kg/m²                     | 1.06 1.04–1.08| 1.03 1.01–1.05                       | 1.11 1.07–1.15                           |
| Alcohol intake, units per week | 1.01 1.00–1.02| 1.01 1.00–1.02                       | 1.03 1.01–1.04                           |
| Antihypertensive medication use | 2.01 1.60–2.52| 2.01 1.60–2.52                       | 2.01 1.60–2.52                           |
| Serum creatinine, µmol/L       | 1.00 0.99–1.00| 1.00 0.99–1.00                       | 1.01 0.99–1.02                           |
| Total cholesterol, mmol/L      | 1.26 1.15–1.38| 1.25 1.11–1.41                       | 1.23 1.07–1.41                           |
| Smoking                        |               |                                      |                                          |
| Past                           | 0.98 0.80–1.19| 0.97 0.75–1.26                       | 1.02 0.74–1.41                           |
| Current                        | 1.03 0.79–1.33| 0.92 0.64–1.31                       | 1.10 0.75–1.62                           |
| Study cohort                   | 1.79 1.29–2.48| 1.40 1.04–1.81                       | 2.09 1.31–3.32                           |
| Plasma homocysteine, µmol/L    | 1.00 0.98–1.02| 0.98 0.96–1.00                       | 1.06 1.02–1.10                           |
| MTHFR genotype                 |               |                                      |                                          |
| CT                             | 1.18 0.98–1.43| 1.35 1.05–1.73                       | 0.98 0.73–1.32                           |
| TT                             | 1.42 1.07–1.90| 1.40 0.95–2.06                       | 1.37 0.88–2.11                           |

CI confidence interval, OR odds ratio

*Data analysed by logistic regression to predict hypertension as the categorical dependent variable; hypertension defined as systolic BP of ≥ 140 and/or a diastolic BP of ≥ 90 mmHg [1]*

*As a binary (yes/no) covariate

*Comparing TUDA cohort with NANS cohort (reference category). See supplementary Table S1 for participant characteristics presented separately for each study cohort

*CT (heterozygous) and TT (homozygous variant) genotypes for the MTHFR 677C→T polymorphism; reference category is the CC genotype

### Table 3 Blood pressure and rates of hypertension in adulthood by MTHFR genotype

| MTHFR genotype | CC (wild type) | CT (heterozygous) | TT (homozygous variant) | P value* |
|----------------|----------------|-------------------|------------------------|----------|
| Total cohort (up to 90 years) | n = 2635 | n = 2606 | n = 719 | 0.806 |
| Age, years | 68.9 (68.3, 69.5) | 69.0 (68.4, 69.6) | 68.6 (67.5, 69.7) | 0.373 |
| Systolic BP, mmHg | 140.7 (139.8, 141.5) | 141.5 (140.8, 142.4) | 141.1 (139.6, 142.6) | 0.258 |
| Diastolic BP, mmHg | 78.0 (77.6, 78.4) | 78.5 (78.0, 78.9) | 78.4 (77.6, 79.2) | 0.302 |
| Hypertension, n (%) | 1373 (51%) | 1411 (53%) | 373 (50%) | 0.302 |
| Adults 18 to 70 years | n = 1124 | n = 1138 | n = 313 | 0.835 |
| Age, years | 56.3 (55.4, 57.1) | 56.4 (55.6, 57.3) | 55.8 (54.2, 57.5) | 0.026 |
| Systolic BP, mmHg | 135.0 (133.9, 136.0)* | 136.1 (135.0, 137.2)* | 137.6 (135.5, 139.6)* | 0.013 |
| Diastolic BP, mmHg | 79.4 (78.9, 80.0)* | 80.0 (79.4, 80.5)* | 81.4 (80.3, 82.5)* | 0.072 |
| Hypertension, n (%) | 464 (40) | 514 (44) | 149 (46) | 0.003 |

CC (wild type), CT (heterozygous), TT (homozygous variant), genotypes for the MTHFR 677C→T polymorphism

Data are expressed as mean (95% CI) for age, as adjusted mean (95% CI) for blood pressure, and n (%) for hypertension

BP blood pressure

*Hypertension defined as systolic BP of ≥ 140 and/or a diastolic BP of ≥ 90 mmHg [1]

*Differences in blood pressure between genotype groups were assessed by one-way ANCOVA with adjustment for age, sex, BMI, alcohol, total cholesterol, antihypertensive drugs use and study cohort following log-transformation of data for normalisation purposes, as appropriate. Different superscript letters (i.e. a, b) within a row indicate significant differences by Bonferroni post hoc test, whilst the same letter (i.e. a, a) indicates no significant differences. Categorical variables were assessed using chi-square analysis
In the current study, in line with our previous observations [17], BP control was poorer in the TT genotype, with only 30% of treated adults with the TT compared to 37% in CT and 45% in CC genotypes, achieving BP control. Similarly, reported BP control rates for all treated adults are 37% in England [23] and higher in North America, at 54% in the US [5] and 65% in Canada [23]. Irrespective of prevailing rates of treatment or BP control, however, our findings suggest that within a given population, adults with the TT genotype compared to others without this gene variant will be less likely to achieve target BP with routine treatment, but neither the patient nor the physician will be aware of this. The economic implications of suboptimal BP control are considerable, with the direct costs of hypertension estimated in 2009 at $370 billion annually, representing 10% of healthcare expenditures worldwide [24].

Uniquely, this study enabled the genetic risk of hypertension owing to this polymorphism to be considered in relation to riboflavin (the MTHFR cofactor). Unlike other B vitamins (e.g. folate and vitamin B12), riboflavin
biomarkers are rarely measured in human studies and no previous cohort study to have investigated this polymorphism has considered riboflavin [25]. We estimated a 3-fold increased risk of hypertension when the variant TT genotype occurred in combination with deficient riboflavin status (relative to the CC genotype and normal riboflavin status), whereas better riboflavin status was associated with reducing the excess hypertension risk, and normal riboflavin status with no genetic risk. In contrast, among adults with CT or CC genotypes, riboflavin status did not influence the risk of hypertension, evidence that riboflavin has a genotype-specific role in BP. The finding that riboflavin has the potential to modify BP in adults affected by this polymorphism is entirely consistent with our earlier studies in hypertensive patients, which showed a lowering of systolic BP by 6 to 13 mmHg in response to riboflavin supplementation specifically in the TT genotype [15–17], resulting in a marked increase in blood-pressure control from 32 to 57% (pre versus post riboflavin intervention for 16 weeks), despite no change in antihypertensive treatment over the intervention period [17]. Here we show the potential of riboflavin to modify BP in genetically at-risk adults at an earlier age and the data suggest that the onset of hypertension could be delayed through intervention with riboflavin. Ideally, such intervention would occur prior to commencing antihypertensive treatment and along with lifestyle interventions as per ESC/ESH guidelines for hypertension management [1], especially considering that riboflavin is safe with no known adverse effects even at doses of 100-fold higher than typical dietary intakes [26]. Alternatively, riboflavin could be co-administered with an antihypertensive drug as a novel combination therapy targeted at patients with this genetic risk factor. The potential to prevent or treat hypertension in sub-populations worldwide could be considerable, given that this genotype affects 10% of people globally, ranging 4–26% in Europeans (increasing north to south), 20% in Northern China, to as high as 32% in Mexico [11].

The impact of this polymorphism on BP throughout adulthood and the potential modifying effect of riboflavin are important findings, considering that this polymorphism is linked with an increased risk of stroke [12–14], and recent evidence shows that living longer in better cardiovascular health during mid-life is associated with lower risk of disease and mortality later in life [27]. Control of BP is highly effective in reducing cardiovascular mortality [5, 23, 24], with each 2 mmHg lower systolic BP associated with a 10% lower risk of stroke [4]. Furthermore, powerful evidence, from the SPRINT trial testing the effects of intensive versus standard blood-pressure control [28] and from meta-analyses of large-scale BP lowering trials [29], highlights significant benefits for cardiovascular risk especially among middle-aged adults [30] of BP-lowering to values below hypertension cut-points. Because of concerns that intensive treatment of BP could also pose certain risks [31], however, there have been calls for newer approaches, including novel combination therapies and non-pharmacological solutions [32]. Our results indicate that the most effective timeframe to target adults with this genetic variant will be up to 70 years, via supplementation with riboflavin to potentially offer an effective low-cost strategy to lower BP. Of note, sub-optimal riboflavin status may be more widespread than is generally recognised, but is largely undocumented as riboflavin biomarkers are rarely measured in human studies [25]. The UK is one of the very few countries worldwide to include a riboflavin biomarker in its population-wide diet and nutrition survey, and recent data shows that over 50% of healthy British adults have low or deficient riboflavin status [33], in close agreement with the current results in Irish adults.

The biological mechanism explaining MTHFR-BP relationship shown here is unknown, but likely involves the potent vasodilator nitric oxide (NO) [34]. Vascular tissue concentrations of 5-methyltetrahydrofolate (the product of the MTHFR reaction) were associated with NO bioavailability and improved endothelial function in patients undergoing coronary artery bypass graft surgery and were found to be lower in those patients with the TT genotype [35, 36]. The current results, considered with our earlier trials [15–17], indicate that the biologic perturbation leading to higher BP in the TT genotype is modifiable with riboflavin. Molecular studies show that the decreased enzyme activity in the TT genotype is owing to loss of the riboflavin (FAD) cofactor from the active site [37], but riboflavin intervention can restore MTHFR activity in vivo [38]. Restoring MTHFR in vascular tissue could in turn lower BP specifically in individuals with the TT genotype. Mechanistic studies are required, but at this time, the evidence does not support a direct role for homocysteine in BP. Although elevated homocysteine is the characteristic phenotype linked with this polymorphism (and is responsive to riboflavin in the TT genotype [38]), intervention trials to lower homocysteine have shown no corresponding BP response [39], indicating that homocysteine is not causatively related to hypertension. The current results suggest that this polymorphism is linked with CVD via BP independently of homocysteine, and given its importance for clinical outcomes, BP may be the much more relevant target to prevent CVD in those affected by the variant genotype.

A strength of this study is its large sample of adults 18 to 90 years stratified for the relevant polymorphism using data from two cohorts sampled under a common project initiative, from participating centres in Northern Ireland (UK) and the Republic of Ireland (representing two distinct health systems), using standardised
methodologies and centralised laboratory analysis to investigate outcomes that were formulated before data collection. Furthermore, the current analysis was based on an a priori hypothesis (linking this polymorphism and riboflavin with BP) whereas other studies of genetic risk factors in relation to disease risk factors are typically opportunistic studies using available data. Thus uniquely, our study provides biomarker data for riboflavin, rarely measured in nutritional studies, and used here to enable the impact of riboflavin on the MTHFR-BP relationship from young adulthood to be demonstrated. The major limitation of this study is its cross-sectional (rather than a longitudinal) design; nonetheless, the study findings in relation to the genotype-specific effect of riboflavin are reinforced by our earlier trials [15–17] showing significant BP-lowering in response to intervention with riboflavin in CVD patients identified with the relevant genotype.

**Conclusion**

The variant *MTHFR 677TT* genotype is associated with higher BP independently of homocysteine and predisposes adults to an increased risk of hypertension and poorer BP control with antihypertensive treatment, whilst better riboflavin status is associated with a reduced genetic risk. Supplemental riboflavin could therefore offer a stratified approach to delay the onset of hypertension and/or improve blood-pressure control in adults with the TT genotype, representing 10% of people globally and higher in some populations. Such an approach aligns with international strategies of personalising treatments to improve cardiovascular health, but the findings require confirmation in randomised trials in non-hypertensive adults.

**Supplementary information**

**Supplementary information** accompanies this paper at https://doi.org/10.1186/s12916-020-01780-x.

**Additional file 1:** Table S1 General study characteristics by NANS and TUDA cohorts. Table S2 Blood pressure and use of antihypertensive drugs in adults 18–70 years by *MTHFR* genotype.

**Abbreviations**

BP: Blood pressure; CVD: Cardiovascular disease; EGRac: Erythrocyte glutathione activation coefficient; FAD: Flavin adenine dinucleotide; GWAS: Genome-wide association studies; MTHFR: Methylenetetrahydrofolate reductase; NANS: National Adult Nutrition Survey; SNPs: Single nucleotide polymorphisms; TUDA: Trinity-Ulster Department of Agriculture

**Acknowledgements**

This paper is dedicated to the memory of John M Scott who inspired this research and was responsible for the original study concept.

**Authors’ contributions**

The authors’ contributions were as follows: HM, MW and JMS conceptualised and designed the study. All authors completed the acquisition, analysis and interpretation of the data. HM, MW, JJ, AMM, JMS, CC, MC, MG and AF obtained study funding. HM, MW, CFH, JJ, RR, CC, AMM, GH, KM, MOK, MJG, AF, JW, BAM, AMcC, LK and JMS were responsible for the methodology. HM, MW, JJ, CC, AMM, AF and JMS provided study supervision. MW and HM drafted the original version of the manuscript. All authors critically revised drafts of the manuscript and approved the final version.

**Funding**

Supported by governmental funding from the Irish Department of Agriculture, Food and the Marine and Health Research Board (under the Food Institutional Research Measure, IRIM, initiative) and from the Northern Ireland Department for Employment and Employment (under its Strengthening the All-Island Research Base initiative). The work combines two studies completed as part of an All-Ireland initiative under the Joint Irish Nutrigenomics Organisation, JINGO. The funders had no role in the study design, in the collection, analysis or interpretation of the data, in the writing of the report, or in the decision to submit for publication.

**Availability of data and materials**

Data from this study are held in full compliance with Ulster University’s Research Governance and Ethics Policy for Human Research (2018) https://internal.ulster.ac.uk/research/office/offceeg.php, which in turn is fully aligned with the UK’s Data Protection Act 2018. The data underlying the results presented in the study are available from Mr. Nick Curry, Head of Research Governance at Ulster University at ncurry@ulster.ac.uk.

**Ethics approval and consent to participate**

TUDA: Ethical approval was obtained from the Office for Research Ethics Committees Northern Ireland (reference number 08/NIR03/113), the Research Ethics Committee in St James’s Hospital, and the Adelaide and Meath Hospital, Dublin. All participants provided written informed consent at the time of recruitment.

NANS: The study was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals, University College Cork, and the Human Ethics Research Committee of University College Dublin. All eligible and willing participants gave their written consent according to the Helsinki declaration.

**Consent for publication**

Not applicable.

**Competing interests**

There is a patent granted in Europe and pending elsewhere by Ward, McNulty, Strain, Horigan and Scott, on the use of riboflavin in the treatment of hypertension; the other authors have no conflicts of interest to declare.

**Authors details**

1The Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, UK. 2The Department of Gerontology, St James’s Hospital, Dublin, Ireland. 3School of Medicine and School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland. 4Clinical Chemistry Laboratory, Western Health and Social Care Trust, Altnagelvin Hospital, Londonderry, Northern Ireland, UK. 5School of Agriculture and Food Science, University College Dublin, Dublin, Ireland. 6School of Food and Nutritional Sciences, University College Cork, Cork, Ireland.

**Received:** 1 June 2020 **Accepted:** 10 September 2020

**Published online:** 11 November 2020

**References**

1. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnett M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.

2. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017;389:37–55.

3. Chow CK, Teo KK, Ranganagarjan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959–68.
4. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.

5. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2016 update. Circulation. 2015;133:e38–48.

6. Newton-Clark C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666–76.

7. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Caspian D, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:193–9.

8. Yang B, Fan S, Zhi X, Li Y, Liu Y, Wang D, et al. Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: a meta-analysis from 114 studies with 15411 cases and 21970 controls. PLoS One. 2014;9:e87497.

9. Yang KM, Jia J, Mao LN, Men C, Tang KT, Li YY, et al. Methylene tetrahydrofolate reductase C677T gene polymorphism and essential hypertension: a meta-analysis of 10,415 subjects. Biomed. Rep. 2014;2:699–708.

10. Niu WQ, You YG, Qi Y. Strong association of methylenetetrahydrofolate reductase gene C677T polymorphism with hypertension and hypertension-in-pregnancy in Chinese: a meta-analysis. J Hum Hypertens. 2012;26:259–67.

11. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, et al. Geographical and ethnic variation of the 677→T allele of 5,10-methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas worldwide. J Med Genet. 2003;40:619–25.

12. Casas JP, Bautista LE, Smeeth L, Ottersen GD, Prestwich SJ, Tunstall-Pedoe H, et al. Homocysteine and cardiovascular disease: systematic review and meta-analysis of prospective studies in two large European populations. BMJ. 2004;328:1709–11.

13. Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Hoeft BA, et al. Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and eNOS coupling. Circulation. 2006;114:86–92.

14. McNulty H, Strain JJ, Hughes CF, Ward M. Riboflavin, MTHFR genotype and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224–32.

15. Holmes MV, Newcombe P, Hubacek J, Sopaske R, Picketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378:894–904.

16. Wilson CP, Ward M, Hoey L, Hughes CF, McNulty H. Riboflavin lowers homocysteine in individuals homozygous for the 677→T polymorphism in MTHFR. J Hypertens. 2010;28:478–86.

17. Porter KM, Ward M, McNulty H, Strain JJ, Trouton TG, Horigan G, et al. Associations of MTHFR gene polymorphisms with hypertension and cardiovascular disease outcomes in adults aged ≥25 years: a randomized clinical trial. JAMA. 2016;315:2673–82.

18. Ettedad HA, Emdin CA, Kiaran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67.

19. Wilson CP, Ward M, McNulty H, Strain JJ, Trouton TG, Horigan G, et al. Methyltetrahydrofolate reductase C677T gene polymorphism and essential hypertension: a meta-analysis of 10,415 subjects. Biomed. Rep. 2014;2:699–708.

20. NCI. Dietary Reference Values for Energy and Macronutrients. DH, London: 2011.

21. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Dietary reference values for riboflavin. EFSA J. 2017;15:46919.

22. Casas JP, Bautista LE, Smeeth L, Ottersen GD, Prestwich SJ, Tunstall-Pedoe H, et al. Homocysteine and cardiovascular disease: systematic review and meta-analysis of prospective studies in two large European populations. BMJ. 2004;328:1709–11.

23. McNulty H, Ward M, Hoey L, Hughes CF, Pentieva K. Addressing optimal folate and related B-vitamin status through the lifecycle: health impacts and challenges. Proc Nutr Soc. 2019;78:449–62.

24. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Dietary reference values for riboflavin. EFSA J. 2017;15:46919.

25. McNulty H, Ward M, Hoey L, Hughes CF, Pentieva K. Addressing optimal folate and related B-vitamin status through the lifecycle: health impacts and challenges. Proc Nutr Soc. 2019;78:449–62.

26. Public Health England. National Diet and Nutrition Survey Results from Years 1, 2, 3 and 4 (combined) of the Rolling Programme (2008/2009–2011/2012). 2014.

27. McNulty H, Strain JJ, Hughes CF, Pentieva K, Ward M. Evidence of a role for one-carbon metabolism in blood pressure: can B vitamin intervention address the genetic risk of hypertension owing to a common folate polymorphism? Curr Dev Nutr. 2020;4:knz102.

28. Antoniades C, Shirodaria C, Warrick N, Cai S, De Bono J, Lee J, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and eNOS coupling. Circulation. 2006;114:1193–201.

29. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:435–43. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/339317/SACN_Dietary_Reference_Values_for_Energy.pdf.

30. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Dietary Reference Values for Energy and Macronutrients. DH, London: 2011.

31. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Dietary Reference Values for Energy and Macronutrients. DH, London: 2011.

32. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–43. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/339317/SACN_Dietary_Reference_Values_for_Energy.pdf.

33. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Dietary Reference Values for Energy and Macronutrients. DH, London: 2011.

34. McNulty H, Strain JJ, Hughes CF, Pentieva K, Ward M. Evidence of a role for one-carbon metabolism in blood pressure: can B vitamin intervention address the genetic risk of hypertension owing to a common folate polymorphism? Curr Dev Nutr. 2020;4:knz102.

35. Antoniades C, Shirodaria C, Warrick N, Cai S, De Bono J, Lee J, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and eNOS coupling. Circulation. 2006;114:1193–201.

36. Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Cunnington C, et al. MTHFR 677 C>T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation. 2009;119:2507–15.

37. Pejchal R, Campbell E, Guenther BD, Lennon BW, Matthews RG, Ludwig ML. Structural perturbations in the Ala→Val polymorphism of methyltetrahydrofolate reductase: how binding of folates may protect against inactivation. Biochemistry. 2006;45:4808–18.

38. McNulty H, Dowey LRC, Strain JJ, Dunne A, Ward M, Molloy AM, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation. 2006;113:74–80.

39. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–73.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.